Pionyr Immunotherapeutics
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
Industries
Nr. of Employees
medium (51-250)
Pionyr Immunotherapeutics
South San Francisco, California, United States, North America
Patents
Products
PY314
A clinical program targeting TREM2 for depleting certain tumor-associated macrophages to enhance anti-tumor response.
PY159
A clinical program targeting TREM1 aimed at repolarizing tumor-associated macrophages to counteract immunosuppression.
PY265
An IND-ready program targeting MARCO to activate the immune system against tumor microenvironment.
PY314
A clinical program targeting TREM2 for depleting certain tumor-associated macrophages to enhance anti-tumor response.
PY159
A clinical program targeting TREM1 aimed at repolarizing tumor-associated macrophages to counteract immunosuppression.
PY265
An IND-ready program targeting MARCO to activate the immune system against tumor microenvironment.